Neurocrine Biosciences
NBIX
S$171.13
Share price
1.71%
Change (1 day)
-13.64%
Change (1 year)
Categories
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.
Neurocrine Biosciences (NBIX) - Total liabilities
Total liabilities on the balance sheet as of March 2025 : S$1.47 Billion
According to Neurocrine Biosciences 's latest financial reports the company's total liabilities are S$1.47 Billion. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Neurocrine Biosciences - Total liabilities on balance sheet (from 2001 to 2025)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2024-12-31 | S$1.53 B | 13.99% |
| 2023-12-31 | S$1.34 B | 51.95% |
| 2022-12-31 | S$0.88 B | -6.17% |
| 2021-12-31 | S$0.94 B | 17.3% |
| 2020-12-31 | S$0.80 B | -10.76% |
| 2019-12-31 | S$0.90 B | 28.87% |
| 2018-12-31 | S$0.69 B | 17.49% |
| 2017-12-31 | S$0.59 B | 719.89% |
| 2016-12-31 | S$72.66 M | 2.07% |
| 2015-12-31 | S$71.19 M | 56.93% |
| 2014-12-31 | S$45.36 M | 4.5% |
| 2013-12-31 | S$43.41 M | -14.68% |
| 2012-12-31 | S$50.88 M | -49.81% |
| 2011-12-31 | S$0.10 B | -37.07% |
| 2010-12-31 | S$0.16 B | 71.64% |
| 2009-12-31 | S$93.87 M | -19.37% |
| 2008-12-31 | S$0.11 B | -48.78% |
| 2007-12-31 | S$0.22 B | 97.75% |
| 2006-12-31 | S$0.11 B | -25.78% |
| 2005-12-31 | S$0.15 B | -24.29% |
| 2004-12-31 | S$0.20 B | -26.51% |
| 2003-12-31 | S$0.27 B | 279.38% |
| 2002-12-31 | S$73.37 M | 10.23% |
| 2001-12-31 | S$66.56 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Repligen
RGEN | S$1.11 B | -24.77% | 🇺🇸 USA |
 Royalty Pharma RPRX | S$10.02 B | 578.78% | 🇬🇧 UK |
 Palatin Technologies PTN | S$12.96 M | -99.12% | 🇺🇸 USA |
 Eli Lilly LLY | S$94.28 B | 6,283.85% | 🇺🇸 USA |
 AbbVie ABBV | S$172.70 B | 11,592.97% | 🇺🇸 USA |
 Pfizer PFE | S$150.50 B | 10,090.19% | 🇺🇸 USA |
 ANI Pharmaceuticals ANIP | S$1.08 B | -26.31% | 🇺🇸 USA |
 Athersys ATHX | S$56.18 M | -96.20% | 🇺🇸 USA |